Daiichi Sankyo Company, LimitedTSE: 4568

Consolidated Financial Statements and Independent Auditor's Report for FY2025PDF

Jun 19, 2026 at 6:08 AM UTC · Issued by Daiichi Sankyo Company, Limited

Watch Daiichi Sankyo explain itDaiichi Sankyo Co Ltd Ord (DSKYF) Q1 2026 Earnings Call · Replay · Jul 31

Consolidated Financial Statements and Independent Auditor's Report For the year ended 31 March, 2026

Daiichi Sankyo Company, Limited

Disclaimer: This document is a translation of the original Japanese version and provided for reference purposes only. In the event of any discrepancy between the Japanese original and this English translation, the Japanese original shall prevail.

Contents

Page

Consolidated Statement of Financial Position 1
Consolidated Statement of Profit or Loss 3
Consolidated Statement of Comprehensive Income 4
Consolidated Statement of Changes in Equity 5
Consolidated Statement of Cash Flows 7
Notes to the Consolidated Financial Statements
1. Reporting Entity 8
2. Basis of Preparation 8
3. Material Accounting Policies 9
4. Significant Accounting Judgments, Estimates and Assumptions 18
5. Standards and Interpretations Issued but Not Yet Adopted 19
6. Operating Segment Information 20
7. Business Combination 21
8. Cash and Cash Equivalents 21
9. Trade and Other Receivables 22
10. Other Financial Assets 23
11. Inventories 25
12. Assets Held for Sale and Liabilities Directly Associated with Assets Held for Sale 25
13. Property, Plant and Equipment 26
14. Goodwill and Intangible Assets 28
15. Investments Accounted for Using the Equity Method 31
16. Income Taxes 32
17. Trade and Other Payables 36
18. Bonds and Borrowings, and Other Financial Liabilities 36
19. Provisions 38
20. Employee Benefits 40
21. Government Grants 45
22. Capital and Other Components of Equity 45
23. Dividend 47
24. Revenue 48
25. Major Expenses by Nature 50
26. Other Income and Other Expenses 51
27. Financial Income and Financial Expenses 52
28. Earnings Per Share 54
29. Share-based Payments 55
30. Financial Instruments 59
31. Lease Transactions 69
32. Other Comprehensive Income 70
33. Cash Flow Information 71
34. Related Parties 72
35. Commitments 72
36. Major Consolidated Subsidiaries and Associates 73
37. Joint Development and Joint Sales Promotion 74
38. Subsequent Events 75

Independent Auditor's Report

Consolidated Financial Statements 1) Consolidated Statement of Financial Position

ASSETS

Current assets

(Millions of JPY) Note As of March 31, 2025 As of March 31, 2026

Cash and cash equivalents	8,30	639,838	449,807
Trade and other receivables	9	619,101	741,145
Other financial assets	10	80,890	104,736
Inventories	11	514,910	692,378
Other current assets		47,443	32,279
Subtotal		1,902,183	2,020,346
Assets held for sale	12	7,250	122,162
Total current assets		1,909,433	2,142,509
Non-current assets Property, plant and equipment	6,13	498,517	596,563
Goodwill	6,14	108,429	97,353
Intangible assets	6,14	235,839	241,064
Investments accounted for using the equity method	15	5,600	4,918
Other financial assets	10	139,175	194,435
Long-term advance payments		167,428	192,906
Deferred tax assets	16	305,019	465,299
Other non-current assets		86,675	70,338
Total non-current assets		1,546,685	1,862,880
Total assets		3,456,119	4,005,390

LIABILITIES AND EQUITY

Trade and other payables	17,21	579,957	596,856
Bonds and borrowings	18,30	399	404
Other financial liabilities	18	14,720	13,630
Income taxes payable		60,369	88,303
Provisions	19	5,804	49,811
Contract liabilities	24	67,956	74,405
Other current liabilities		24,825	30,060
Subtotal		754,032	853,471
Liabilities directly associated with assets held for sale	12	-	31,552

Current liabilities

(Millions of JPY) Note As of March 31, 2025 As of March 31, 2026

Total current liabilities		754,032	885,023
Non-current liabilities
Bonds and borrowings	18,30	100,933	300,077
Other financial liabilities	18	43,675	39,219
Post-employment benefit liabilities	20	1,559	1,452
Provisions	19	13,030	164,572
Contract liabilities	24	751,038	806,809
Deferred tax liabilities	16	11,066	3,230
Other non-current liabilities	21	157,365	140,825
Total non-current liabilities		1,078,670	1,456,186
Total liabilities		1,832,703	2,341,210
Equity
Equity attributable to owners of the Company
Share capital	22	50,000	50,000
Treasury shares	22	(147,321)	(247,993)
Other components of equity	22	263,693	311,619
Retained earnings		1,457,044	1,550,553
Total equity attributable to owners of the		1,623,416	1,664,179
Company
Total equity		1,623,416	1,664,179
Total liabilities and equity		3,456,119	4,005,390

2) Consolidated Statement of Profit or Loss			(Millions of JPY)
	Note	Year ended March 31, 2025	Year ended March 31, 2026
Revenue	6,24	1,886,256	2,123,045
Cost of sales	25	415,797	669,045
Gross profit		1,470,458	1,454,000
Selling, general and administrative expenses	25	731,200	780,683
Research and development expenses	25	435,965	466,005
Other income	26	28,739	22,100
Other expenses	26	107	323
Operating profit		331,925	229,089
Financial income	27	34,103	40,815
Financial expenses	27	11,854	7,986
Share of profit (loss) of investments accounted for using the equity method	15	1,457	1,513

Profit before tax		355,631	263,432
Income taxes	16	59,874	3,558
Profit for the year		295,756	259,874
Profit attributable to:
Owners of the Company		295,756	259,874
Earnings per share Basic earnings per share (JPY)	28	155.96	140.44
Diluted earnings per share (JPY)		155.87	140.37

Consolidated Statement of Comprehensive Income

(Millions of JPY) Note Year ended March 31, 2025 Year ended March 31, 2026

Profit for the year 295,756 259,874

Other comprehensive income

Items that will not be reclassified to profit or loss

Financial assets measured at fair value through other comprehensive income	16	5,252	4,753
Remeasurements of defined benefit plans	16	3,702	(4,981)
Items that may be reclassified subsequently to profit
or loss
Exchange differences on translation of foreign operations	16,32	(15,790)	50,185
Cash flow hedges	16,30,32	886	77
Other comprehensive income for the year		(5,948)	50,034
Total comprehensive income for the year		289,808	309,908
Total comprehensive income attributable to:
Owners of the Company		289,808	309,908

Consolidated Statement of Changes in Equity

Year ended March 31, 2025

Equity attributable to owners of the Company

(Millions of JPY)

Note

Share capital Capital surplus Treasury shares

Other components of equity

Exchange differences on

Financial assets measured at fair

Subscription

rights to shares

translation of foreign operations

Cash flow

hedges

value through

other comprehensive income

Balance as of April 1, 2024 50,000 1,962 (36,629) 560 243,928 (232) 39,742

Profit for the year - - - - - - -

Other comprehensive

- - - - (15,790) 886 5,252

income for the year

Total comprehensive - - - - (15,790) 886 5,252 income for the year

Purchase of treasury shares - (90) (245,975) - - - -Disposal of treasury shares - - 960 (135) - - -

Cancellation of treasury 22 - (7,547) 134,323 - - - -

Dividend 23 - - - - - - -Share-based compensation - 5,675 - - - - -

Change in ownership - - - - - - -interest in subsidiaries

Transfer from other

components of equity to retained earnings Transfer to non-financial

- - - - - - (9,864)

assets and similar items - - - - - (654) -

Others - - - - - - -

Total transactions with

- (1,962) (110,691) (135) - (654) (9,864)

owners of the Company

Balance as of March 31, 2025 50,000 - (147,321) 424 228,137 - 35,130

(Millions of JPY)

Equity attributable to owners of the Company

Other components of equity

Total equity

Note Remeasure-

ments of defined benefit

Total other components of equity

Retained earnings

attributable to owners of the

	-	283,998	1,388,842	1,688,173	429	1,688,603
	-	-	295,756	295,756	-	295,756
	3,702	(5,948)	-	(5,948)	-	(5,948)
	3,702	(5,948)	295,756	289,808	-	289,808
	-	-	-	(246,066)	-	(246,066)
	-	(135)	(503)	320	-	320
22	-	-	(126,775)	-	-	-
23	-	-	(114,408)	(114,408)	-	(114,408)
	-	-	-	5,675	-	5,675
	-	-	-	-	(429)	(429)
	(3,702)	(13,566)	13,566	-	-	-
-		(654)	-	(654)	-	(654)
-		-	566	566	-	566
(3,702)		(14,356)	(227,554)	(354,565)	(429)	(354,995)
-		263,693	1,457,044	1,623,416	-	1,623,416

Company

Non-controlling

interests

Total equity

Balance as of April 1, 2024 Profit for the year

Other comprehensive

income for the year Total comprehensive income for the year

Purchase of treasury shares Disposal of treasury shares Cancellation of treasury shares

Dividend

Share-based compensation Change in ownership interest in subsidiaries Transfer from other components of equity to retained earnings

Transfer to non-financial assets and similar items Others

Total transactions with owners of the Company

Balance as of March 31, 2025

plans

Year ended March 31, 2026

Note

Equity attributable to owners of the Company

Other components of equity

Exchange

(Millions of JPY)

Financial assets

Share capital Capital surplus Treasury shares

Subscription rights to shares

differences on translation of foreign

operations

Cash flow hedges

measured at fair

value through other comprehensive

Balance as of April 1, 2025 Profit for the year

Other comprehensive

income for the year

Total comprehensive income for the year

income

Purchase of treasury shares Disposal of treasury shares Cancellation of treasury

Dividend

Share-based compensation Transfer from other components of equity to retained earnings

Transfer to non-financial assets and similar items Others

Total transactions with owners of the Company Balance as of March 31, 2026

	50,000 -	- -	(147,321) -	424 -	228,137 -	- -	35,130 -
	-	-	-	-	50,185	77	4,753
	-	-	-	-	50,185	77	4,753
	-	(115)	(150,342)	-	-	-	-
	-	-	535	(42)	-	-	-
22	-	(8,629)	48,971	-	-	-	-
23	-	-	-	-	-	-	-
	-	8,745	164	-	-	-	-
	-	-	-	-	-	-	(7,141)
	-	-	-	-	-	(77)	-
	-	-	-	-	171	-	-
	-		(100,671)	(42)	171	(77)	(7,141)
	50,000	-	(247,993)	381	278,494	-	32,743

(Millions of JPY)

Equity attributable to owners of the Company

Other components of equity

Total equity

Note Remeasure-

ments of defined benefit

Total other

	-	263,693	1,457,044	1,623,416	1,623,416
	-	-	259,874	259,874	259,874
	(4,981)	50,034	-	50,034	50,034
	(4,981)	50,034	259,874	309,908	309,908
	-	-	-	(150,458)	(150,458)
	-	(42)	(221)	271	271
22	-	-	(40,341)	-	-
23	-	-	(128,527)	(128,527)	(128,527)
	-	-	-	8,909	8,909
	4,981	(2,159)	2,159	-	-
	-	(77)	-	(77)	(77)
	-	171	566	737	737
	4,981	(2,108)	(166,365)	(269,145)	(269,145)
	-	311,619	1,550,553	1,664,179	1,664,179

components of equity

Retained earnings

attributable to owners of the

Company

Total equity

Balance as of April 1, 2025 Profit for the year

Other comprehensive

income for the year Total comprehensive income for the year

Purchase of treasury shares Disposal of treasury shares Cancellation of treasury shares

Dividend

Share-based compensation Transfer from other components of equity to retained earnings

Transfer to non-financial assets and similar items Others

Total transactions with owners of the Company Balance as of March 31, 2026

plans

Consolidated Statement of Cash Flows

Note Year ended March 31,

2025

(Millions of JPY) Year ended March 31,

2026

(Consolidated statement of financial position)

Cash flows from operating activities
Profit before tax			355,631		263,432
Depreciation and amortization			68,649		77,460
Impairment losses (reversal of impairment losses)			3,094		5,967
Financial income			(34,103)		(40,815)
Financial expenses			11,854		7,986
Share of (profit) loss of investments accounted for using the equity
method		(1,457)		(1,513)
(Gain) loss on sale and disposal of non-current assets		(1,276)		3,927
(Increase) decrease in trade and other receivables		(167,750)		(104,620)
(Increase) decrease in inventories		(78,367)		(172,748)
(Increase) decrease in long-term advance payments		(50,488)		(25,477)
Increase (decrease) in trade and other payables		40,106		(10,501)
Increase (decrease) in provisions		(11,361)		195,662
Increase (decrease) in contract liabilities		81,420		61,907
Others, net		(75,122)		(72,628)
Subtotal		140,829		188,038
Interest and dividend received		23,226		20,307
Interest paid		(1,929)		(2,238)
Income taxes paid		(108,283)		(128,451)
Net cash flows from (used in) operating activities		53,842		77,655
Cash flows from investing activities
Payments into time deposits		(15,984)		(131,739)
Proceeds from maturities of time deposits		356,727		98,121
Acquisition of securities		(207,248)		(101,896)
Proceeds from sale and redemption of securities		382,281		130,219
Acquisition of property, plant and equipment		(116,259)		(128,365)
Proceeds from sale of property, plant and equipment		499		17
Acquisition of intangible assets		(71,613)		(20,637)
Proceeds from sale of subsidiaries and affiliates	33	5,250		8,350
Loan advances		-		(1)
Proceeds from collection of loans receivable		18		17
Others, net		499		(2,328)
Net cash flows from (used in) investing activities		334,170		(148,241)
Cash flows from financing activities
Proceeds from bonds and borrowings	33	-		300,000
Repayments of bonds and borrowings	33	(402)		(100,401)
Purchase of treasury shares		(246,066)		(150,458)
Proceeds from sale of treasury shares		-		0
Dividend paid		(114,317)		(128,430)
Payments of lease liabilities		(16,984)		(18,068)
Others, net		0		(515)
Net cash flows from (used in) financing activities		(377,769)		(97,875)
Net increase (decrease) in cash and cash equivalents		10,242		(168,461)
Cash and cash equivalents at the beginning of the year	8	647,180		639,838
Effect of exchange rate changes on cash and cash equivalents		(17,584)		17,605
Cash and cash equivalents at the end of the year		639,838		488,983
Cash and cash equivalents reclassified to assets held for sale	12	-		(39,176)
Cash and cash equivalents at the end of the year
8		639,838		449,807

Notes to the Consolidated Financial Statements

Reporting Entity
Daiichi Sankyo Company, Limited (the "Company") is a public company domiciled in Japan. The addresses of its registered head office and principal business locations are disclosed on the Company's website (https://www.daiichisankyo.co.jp). The Company and its subsidiaries (collectively the "Group") are engaged in manufacturing and marketing of pharmaceutical products.
The Group's consolidated financial statements for the year ended March 31, 2026 were approved on June 19, 2026 by Hiroyuki Okuzawa, Representative Director, President and CEO.
Basis of Preparation
1. Compliance with International Financial Reporting Standards
  The consolidated financial statements of the Group have been prepared in accordance with International Financial Reporting Standards ("IFRS") under Article 312 of the Ordinance on Terminology, Forms, and Preparation Methods of Consolidated Financial Statements, as the Group meets the criteria of a "Specified Entity" defined under Article 1-2 of this ordinance.
2. Basis of Measurement
  The Group's consolidated financial statements have been prepared on a historical cost basis except for certain financial instruments and other items as described in Note 3 "Material Accounting Policies."
3. Functional Currency and Presentation Currency
  The Group's consolidated financial statements are presented in Japanese Yen ("JPY"), which is the functional currency of the Company. All financial information presented in JPY has been rounded down to the nearest million JPY.
4. Changes in Accounting Policies
  The Material Accounting Policies adopted in preparing the consolidated financial statements of the Group have not changed from the prior year.
5. Changes in Presentation
  (Consolidated Statement of Financial Position)
  "Long-term advance payments", which was included in "Other non-current assets" under non-current assets in the previous consolidated fiscal year, is disclosed separately for the fiscal year ended March 31, since the monetary significance has increased.
  To reflect this change in presentation, the Consolidated Statement of Financial Position as of March 31, 2025 has been reclassified on a consistent basis.
  As a result, the amount of JPY 254,104 million reported in "Other non-current assets" under non-current assets in the Consolidated Statement of Financial Position as of March 31, 2025 has been reclassified as "Long-term advance payments" of JPY 167,428 million and "Other non-current assets" of JPY 86,675 million.
  (Consolidated Statement of Cash Flows)
  "(Increase) decrease in long-term advance payments" and "Increase (decrease) in provisions", which were included in "Others, net" under cash flows from operating activities in the previous consolidated fiscal year, are disclosed separately for the fiscal year ended March 31, since the monetary significance has increased.
  To reflect this change in presentation, the Consolidated Statement of Cash Flows for the fiscal year ended March 31, 2025, has been reclassified on a consistent basis.
  As a result, the amount of JPY (136,972) million reported in "Others, net" under cash flows from operating activities in the Consolidated Statement of Cash Flows for the fiscal year ended March 31, 2025 has been reclassified as "(Increase) decrease in long-term advance payments" of JPY (50,488) million, "Increase (decrease) in provisions" of JPY (11,361) million and "Others, net" of JPY (75,122) million.
Material Accounting Policies
1. Basis of Consolidation
  1. Subsidiaries
    A Subsidiary is an entity that is controlled by the Group. The Group controls an entity if the Group has power over the entity, exposure, or rights, to variable returns from its involvement with the entity and the ability to use its power over the entity to affect the amount of its returns. Consolidation of a subsidiary begins from the date the Group obtains control of the subsidiary and ceases when the Group loses control of the subsidiary. Changes in a parent's ownership interest in a subsidiary that occur after obtaining the control over the subsidiary and that do not result in the parent losing control of the subsidiary are accounted for as equity transactions.
    All intra-group balances and transactions, and any unrealized gains and losses arising from intra-group transactions, are eliminated in preparing the consolidated financial statements.
  2. Associates
    An associate is an entity over which the Group has significant influence but is not a subsidiary of the Group. Significant influence is the power to participate in the financial and operating policy decisions of the investee but is not control or joint control of those policies.
    An investment is accounted for using the equity method from the date on which the Group has the significant influence until the date on which it ceases to have the significant influence over the investment.
    When significant influence over an associate is lost, and if there is still remaining ownership interest, the remaining equity interest is measured at fair value. The difference between the fair value and the carrying value at the date on which the equity method is discontinued, is recognized in profit or loss.
    Investment in associates includes acquired goodwill.
  3. Joint arrangements
    A joint arrangement is a contractual arrangement based on which two or more parties have joint control. Joint control is the contractually agreed sharing of control of an arrangement, which exists only when decisions about the activities that significantly affect the returns of the arrangement require the unanimous consent of the parties sharing control.
    The Group classifies its involvement with a joint arrangement as a joint operation when the Group has rights to the assets and obligations for the liabilities relating to the arrangement, and accounts for its share of the assets, liabilities, revenue and expenses in relation to its interest in the joint operation.
2. Business Combinations
  Business combinations are accounted for using the acquisition method. The acquisition cost is measured as the sum of the consideration transferred, the amount of non-controlling interest in the acquiree, and in the case of an acquisition achieved in stages, the fair value of the previously held equity interest at the date of acquisition. The consideration transferred is measured at fair value at the date of acquisition. Non-controlling interests are measured either at fair value or at the proportionate share of the acquiree's identifiable net assets for each business combination.
  The excess of the acquisition cost over the Group's share of the acquiree's identifiable assets, liabilities, and contingent liabilities at fair value is recognized as goodwill. When the aggregate amount of the acquiree's identifiable assets, liabilities and contingent liabilities exceeds the acquisition cost, the resulting gain is recognized in profit or loss on the date of acquisition. Acquisition related costs are recognized as expenses in the period they are incurred.
3. Foreign Currency Translation
  Foreign currency transactions are translated into the functional currency using the exchange rates at the dates of the transactions. Foreign currency monetary assets and liabilities are translated into the functional currency using the exchange rates at the end of the reporting period and the exchange differences arising on the settlement of monetary items or on translating monetary items are generally recognized in profit or loss. However, exchange differences arising from the translation of financial assets measured at fair value through other comprehensive income and cash flow hedges are recognized in other comprehensive income.
  Assets and liabilities of foreign operations (including goodwill and fair value adjustments arising on the acquisition of foreign operations) are translated into the presentation currency at the exchange rate at the end of the reporting period. Income and expenses of foreign operations are translated into the presentation currency at the average exchange rate for the period, except for the case that the exchange rates fluctuate significantly. When a subsidiary's functional currency is the currency of a hyperinflationary economy, adjustments are made to its separate financial statements to reflect current price levels, and income and expenses of the subsidiary are translated into the presentation currency at the exchange rate at the end of the reporting period.
  Exchange differences arising from translation of financial statements of foreign operations are recognized in other comprehensive income after the date of transition to IFRS. On the disposal of the entire interest in a foreign operation, or on the partial disposal of the interest in a foreign operation that involves the loss of control of a subsidiary or loss of significant influence over an associate, the cumulative amount of the exchange differences relating to that foreign operation, recognized in other comprehensive income and accumulated as a separate component of equity, is reclassified to profit or loss as a part of gain or loss on disposal.
4. Financial Instruments
  1. Non-derivative Financial Assets
    1. Initial recognition and measurement
      Financial assets are recognized on the contract date when the Group becomes a party to the contractual provisions of the instruments.
      Financial assets, except for financial assets measured at fair value through profit or loss, are measured at fair value plus transaction costs that are attributable to the acquisition of the financial asset. However, trade receivables that do not contain a significant financing component are initially recognized at transaction price. At initial recognition, financial assets are classified as (a) financial assets measured at amortized cost; (b) financial assets measured at fair value through other comprehensive income; or (c) financial assets measured at fair value through profit or loss.
      1. Financial assets measured at amortized cost
        Financial assets are classified as financial assets measured at amortized cost if both of the following conditions are met:
        the financial asset is held within a business model whose objective is to hold the financial asset in order to collect contractual cash flows: and
        the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.
      2. Financial assets measured at fair value through other comprehensive income
        Debt instruments measured at fair value are classified as financial assets measured at fair value through other comprehensive income if both of the following conditions are met:
        the financial asset is held within a business model whose objective is achieved by both collecting contractual cash flows and selling the financial asset: and
        the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.
        For equity instruments measured at fair value, except for equity instruments held for trading which must be measured at fair value through profit or loss, the Group made an irrevocable election to present subsequent changes in fair value of certain equity instruments in other comprehensive income.
      3. Financial assets measured at fair value through profit or loss
        Financial assets, except for financial assets measured at amortized cost and financial assets measured at fair value through other comprehensive income, are classified as financial assets measured at fair value through
        profit or loss.
    2. Subsequent measurement
      After initial recognition, financial assets are measured based on their classification as follows:
      1. Financial assets measured at amortized cost
        Financial assets measured at amortized cost are measured at amortized cost using the effective interest method.
      2. Financial assets measured at fair value through other comprehensive income
        Changes in the fair value of debt instruments classified as financial assets measured at fair value through other comprehensive income are recognized in other comprehensive income, except for impairment gains or losses and foreign exchange gain and losses, which are recognized in profit or loss, and the cumulative gain or loss previously recognized in other comprehensive income is reclassified from equity to profit or loss as a reclassification adjustment when debt instruments are derecognized.
        Changes in the fair value of equity instruments designated as financial assets measured at fair value through other comprehensive income are recognized in other comprehensive income, and the accumulated amount of other comprehensive income is transferred to retained earnings when equity instruments are derecognized or the decrease in fair value compared to acquisition cost is significant.
      3. Financial assets measured at fair value through profit or loss
        Financial assets measured at fair value through profit or loss are measured at fair value, and any changes in fair value are recognized in profit or loss.
    3. Derecognition
      Financial assets are derecognized when the contractual rights to the cash flows from the asset expire or are transferred in a transaction in which substantially all the risks and rewards of ownership of the asset are transferred to another entity.
  2. Impairment of Financial Assets
    At the end of each reporting period, the Group evaluates whether the credit risk on financial assets measured at amortized cost has increased significantly since initial recognition, and a loss allowance for expected credit losses on such financial assets is recognized.
    If the credit risk on financial assets has not increased significantly since initial recognition, a loss allowance is measured at an amount equal to 12-month expected credit losses. If the credit risk on financial assets has increased significantly since initial recognition, a loss allowance is measured at an amount equal to lifetime expected credit losses. However, a loss allowance for trade receivables that do not contain a significant financing component is measured at an amount equal to lifetime expected credit losses.
    The Group considers, as a general rule, that there has been a significant increase in the credit risk when payments have not been made for more than 30 days passed contractual due date. The Group considers not only the information regarding due date but also other reasonable and supportable information when determining whether credit risk has increased significantly since initial recognition. The Group considers that there has not been a significant increase in the credit risk when the financial assets are determined to have low credit risk at the end of reporting period.
    Expected credit losses on financial assets are measured in a way that reflects the following factors:
    - an unbiased and probability-weighted amount that is determined by evaluating a range of possible outcomes;
    - the time value of money; and
    - reasonable and supportable information that is available without undue cost or effort at the reporting date about past events, current conditions and forecasts of future economic conditions.
    Expected credit losses are measured based on the discounted present value of the differences between the contractual cash flows and the cash flows expected to be received. When expected credit losses are recognized, the carrying amount of the financial asset is reduced through use of a loss allowance for expected credit losses and expected credit losses are recognized in profit or loss. If, in a subsequent period, the amount of the expected credit losses decreases, the previously recognized credit losses are reversed by adjusting the loss allowance and the reversal is recognized in profit or loss. The carrying amount of financial assets measured at amortized cost is reduced directly when they are expected to become uncollectible in the future and all collaterals are implemented
    or transferred to the Group.
  3. Non-derivative Financial Liabilities
    1. Initial recognition and measurement
      Financial liabilities are classified as financial liabilities measured at amortized cost or financial liabilities measured at fair value through profit or loss at initial recognition.
      At initial recognition, financial liabilities are measured at fair value and, in the case of financial liabilities at amortized cost, the transaction costs that are directly attributable to the issue of the financial liabilities are deducted.
    2. Subsequent measurement
      After initial recognition, financial liabilities are measured based on classification as follows:
      1. Financial liabilities measured at amortized cost
        Financial liabilities measured at amortized cost are measured at amortized cost using the effective interest method. Amortization using the effective interest method and gains or losses arising from termination of recognition are recognized in profit or loss.
      2. Financial liabilities measured at fair value through profit or loss
        Financial liabilities measured at fair value through profit or loss are measured at fair value through profit or loss.
    3. Derecognition
      Financial liabilities are derecognized when the obligation is discharged, cancelled or expired.
  4. Offsetting Financial Assets and Liabilities
    Financial assets and financial liabilities are offset only when the Group has a legally enforceable right to offset the recognized amounts and intends to settle on a net basis or to realize the asset and settle the liability simultaneously.
  5. Derivatives and Hedge Accounting
    Derivatives are utilized to hedge foreign currency risk and interest rate risk. The derivatives primarily used by the Group include forward foreign exchange contracts and interest-rate swaps.
    At the inception of the hedging relationship the Group formally designates and documents the hedging relationship and the entity's risk management objective and strategy for undertaking the hedge. The documentation includes identification of the hedging instrument, the hedged item, the nature of the risk being hedged and how the entity will assess whether the hedging relationship meets the hedge effectiveness requirements.
    The Group assesses at the inception of the hedging relationship, and on an ongoing basis, whether the hedging relationship meets the hedge effectiveness requirements. At a minimum, the Group performs the ongoing assessment at each reporting date or upon a significant change in the circumstances affecting the hedge effectiveness requirements, whichever comes earlier.
    Derivatives are initially recognized at fair value with transaction costs recognized in profit or loss when they are incurred. After initial recognition, derivatives are measured at fair value.
    Hedges that meet the criteria for hedge accounting are accounted for as follows:
    1. Fair value hedges
      Changes in the fair value of the hedging instruments are recognized in profit or loss. Changes in the fair value of hedged items attributable to the hedged risks are recognized in profit or loss, adjusting the carrying amount of the hedged item.
    2. Cash flow hedges
      The effective portion of changes in fair value of hedging instruments is recognized in other comprehensive income, while the ineffective portion is recognized immediately in profit or loss. The cumulative amounts of changes in fair value of hedging instruments recognized in other comprehensive income are reclassified from equity to profit or loss in the same period or periods when the hedged forecast cash flows or hedged items affect profit or loss. If hedged items result in the recognition of non-financial assets or non-financial liabilities, the cumulative amounts recognized in other comprehensive income are accounted for as adjustments in the carrying amount of the non-financial assets or non-financial liabilities. When forecast transactions or firm commitments are no longer expected to occur, any related cumulative gain or loss that has been recognized in other comprehensive income is reclassified from equity to profit or loss. The Group discontinues hedge accounting prospectively only when the hedging relationship ceases to meet the qualifying criteria. This includes instances when the hedging instrument expires or is sold, terminated or exercised.
5. Cash and Cash Equivalents
  Cash and cash equivalents comprise cash on hand, readily available bank deposits, and short-term, highly liquid investments having maturities of three months or less that are readily convertible to known amounts of cash and subject to an insignificant risk of changes in value.
6. Inventories
  Inventories are measured at the lower of cost and net realizable value. Costs of inventories comprise cost of raw materials, direct labor and other costs directly attributable to the inventories and cost of related production overheads. The cost of inventories is assigned by using the weighted average cost formula. Net realizable value is the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale.
7. Property, Plant and Equipment
  Property, plant and equipment is carried at cost less any accumulated depreciation and any impairment losses.
  The cost of an item of property, plant and equipment includes any costs directly attributable to the acquisition of the asset, costs of dismantlement, removal and restoration as well as borrowing costs eligible for capitalization.
  An item of property, plant and equipment, except for land, is depreciated by the straight-line method based on the estimated useful life of the asset. The estimated useful lives of major items of property, plant and equipment are as follows:
  - Buildings and structures: 15 to 50 years
  - Machinery and vehicles: 4 to 8 years
  The depreciation method, the residual value and the useful life of an item of property, plant and equipment are reviewed at least annually and adjusted as necessary.
8. Goodwill and Intangible Assets
  1. Goodwill
    Goodwill is measured at cost less accumulated impairment loss and is not amortized. Goodwill arising from a business combination is allocated to cash-generating units or groups of cash-generating units that are expected to benefit from the synergies of the business combination.
  2. Intangible Assets
    Among rights related to products or research and development acquired separately or through business combinations, those that are still in the research and development stage or those for which marketing approval has not yet been obtained from the regulatory authorities are recognized under intangible assets as "IPR&D."
    The cost of a separately acquired intangible asset is measured at cost and the cost of an intangible asset acquired in a business combination is measured at its fair value at the acquisition date. After initial recognition, the Group applies the cost model and intangible assets are carried at cost less any accumulated amortization and any accumulated impairment loss.
    Internally generated research expenditure is recognized as an expense when it is incurred. Internally generated development expenditure is recognized as an intangible asset if all the criteria for capitalization can be demonstrated. However, due to the uncertainties relating to the research and development duration and process, it is considered that the criteria for capitalization are not met until marketing approval from a regulatory authority is obtained. Therefore, internally generated development expenditure is recognized as an expense when it is incurred. Subsequent expenditure, including initial upfront and milestone payments to the third parties, on an acquired IPR&D is capitalized if, and only if, it is probable that the expected future economic benefits that are attributable to the asset will flow to the Group and the asset is identifiable.
    An intangible asset recognized as IPR&D is not amortized because it is not yet available for use, but instead, it is tested for impairment annually at the same time each year or whenever there is an indication of impairment.
    Once marketing approval from the regulatory authorities is obtained and the asset is available for use, IPR&D is transferred to Commercial rights.
    Acquisition cost and development expenditure of software for internal use is recognized as an intangible asset if it can be demonstrated that the asset will generate probable future economic benefits.
    Intangible assets with finite useful lives are amortized by the straight-line method based on the estimated useful life of the asset, beginning from when the assets are available for use. The estimated useful lives of major items of intangible assets are as follows:
    - Commercial rights: 9 to 18 years
    The amortization method, the residual value and the useful lives of intangible assets are reviewed at least annually and adjusted as necessary.
9. Leases
  1. As a lessee
    The Group recognizes a right-of-use asset and a lease liability at the lease commencement date.
    A right-of-use asset is initially measured at cost and is subsequently depreciated using the straight-line method from the commencement date to the earlier of the end of the useful life of the right-of-use asset or the end of the lease term. The estimated useful lives of right-of-use assets are determined on the same basis as those of tangible fixed assets. In addition, a right-of-use asset is reduced by impairment losses, if any, and adjusted for certain remeasurements of the lease liability.
    A lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Group's incremental borrowing rate.
    Lease payments are allocated to financial expenses and repayments of lease liabilities so that the interest expenses each period during the lease term will result in a constant interest rate on the outstanding lease liability.
    A lease liability is remeasured when there is a change in future lease payments arising from a change in an index or rate, or if the Group changes its assessment of whether it will exercise a purchase, extension or termination option. When a lease liability is remeasured in this way, a corresponding adjustment is made to the carrying amount of the right-of-use asset or is recorded in profit or loss if the carrying amount of the right-of-use asset has been reduced to zero.
    The Group has elected not to recognize right-of-use assets and lease liabilities for short-term leases and leases of low-value assets. The Group recognizes the lease payments associated with these leases as an expense on a straight-line basis over the lease term.
  2. As a lessor
    The Group determines at lease inception whether each lease is a finance lease or an operating lease.
    To classify each lease, if the lease transfers substantially all of the risks and rewards incidental to ownership of the underlying asset, then it is a finance lease; if not, then it is an operating lease.
    When the Group is an intermediate lessor, it accounts for its interests in the head lease and the sub-lease separately. It assesses the lease classification of a sub-lease with reference to the right-of-use asset arising from the head lease, not with reference to the underlying asset. If a head lease is a short-term lease to which the Group applies the exemption described above, then it classifies the sub-lease as an operating lease.
10. Impairment of Non-financial Assets
  The Group assesses annually whether there is any indication that a non-financial asset or cash-generating unit that generates cash inflows may be impaired.
  If there is any indication that an asset or cash-generating unit may be impaired, the recoverable amount of the asset is estimated. Goodwill, intangible assets with indefinite lives, and intangible assets not yet available for use are not amortized but are tested for impairment annually or at any time there is an indication that an asset may be impaired. The recoverable amount of an asset or a cash-generating unit is the higher of its fair value less costs of disposal and its value in use, which is calculated based on the risk-adjusted future cash flows discounted by an appropriate discount rate.
  If the carrying amount of an asset or a cash-generating unit exceeds the recoverable amount, an impairment loss is recognized in profit or loss and the carrying amount is reduced to the recoverable amount.
  An impairment loss recognized for goodwill is not reversed in a subsequent period. It is assessed whether there is any indication that an impairment loss recognized in prior periods for an asset other than goodwill may no longer exist or may have decreased. If any such indication exists, the recoverable amount of the asset or cash-generating unit is estimated. If the recoverable amount exceeds the carrying amount of the asset or cash-generating unit, an impairment loss recognized in prior periods is reversed and the carrying amount of the asset is increased to the recoverable amount. The reversal of the impairment loss is recognized in profit or loss. The increased carrying amount of an asset other than goodwill attributable to a reversal of an impairment loss does not exceed the carrying amount that would have been determined (net of amortization or depreciation) if no impairment loss had been recognized for the asset in prior years.
11. Non-current Assets Held for Sale and Discontinued Operations
  A non-current asset, or disposal group comprising assets and liabilities, is classified as asset held for sale if its carrying amount will be recovered primarily through sale rather than continuing use. The asset or disposal group is classified as held for sale only if it is available for immediate sale in its present condition, and the sale is highly probable meaning that the appropriate level of management of the Group is committed to the sale and principally that the sale is expected to be completed within one year. After the asset or disposal group is classified as held for sale, it is measured at the lower of its carrying amount and fair value less costs to sell and is not depreciated or amortized.
  Discontinued operations include a component of an entity that either has been disposed of or is classified as held-for-sale, and represents a separate major line of business or geographic area of operations.
12. Employee Benefits
  1. Post-employment Benefits
    1. Defined benefit plans
      The present value of defined benefit obligations and related current service cost and, where applicable, past service cost are determined using the projected unit credit method for each plan separately.
      The discount rate is determined by reference to market yields at the end of the reporting period on high-rated corporate bonds, reflecting the estimated timing of benefit payments.
      Net defined benefit liabilities or assets are calculated by deducting the fair value of the plan assets from the present value of the defined benefit obligations.
      If the defined benefit plan has surplus, the defined benefit asset is limited to the asset ceiling that is the present value of any future economic benefits available in the form of reductions in the future contributions to the plan or cash refunds.
      Past service costs are recognized in profit or loss as incurred.
      Remeasurements of defined benefit plans are recognized in other comprehensive income in the period when they are incurred and transferred to retained earnings immediately.
      Service costs and net interest on the net defined benefit liabilities (assets) are recognized in profit or loss.
    2. Defined contribution plans
      The contributions to defined contribution plans are recognized as expenses when the related service is rendered by the employees.
  2. Others
    Short-term employee benefits are not discounted and are recognized as expenses when the related service is rendered by the employees. The expected costs of accumulating short-term compensated absences are recognized as liabilities when the Group has present legal or constructive obligations to pay as a result of past employee service and when reliable estimates of the obligation can be made.
13. Provisions
  A provision is recognized when there is a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation.
  An onerous contract is a contract in which the unavoidable costs of meeting the obligations under the contract exceed the economic benefits expected to be received under the contract. When the Group has an executory contract that includes an onerous contract, the present obligation under the contract is recognized as a provision.
  When the effect of the time value of money is material, the amount of a provision is measured at the present value of the expenditures expected to be required to settle the obligation. The present value is determined by using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks inherent in the liabilities. The increase in the carrying amount of a provision reflecting the passage of time is recognized as a financial expense.
14. Treasury Shares
  Treasury shares are recognized as a deduction from equity. No gain or loss is recognized on the purchase, sale or cancellation of the treasury shares. Any difference between the carrying amount and the consideration paid is recognized in capital surplus.
15. Share-based Payments
  The Company and certain of its subsidiaries operate an equity-settled share-based payment plan and a cash-settled share-based payment plan as share-based payment plans.
  1. Equity-settled share-based payment plan
    The shares are measured at the fair value at the date of grant based on the fair value of the equity instrument granted, and recognized as expenses over the vesting period, with a corresponding increase in equity.
  2. Cash-settled share-based payment plan
    The fair value of the amount of payments is recognized as an expense with a corresponding liability. The change in the fair value of the liability at each reporting date is recognized in profit or loss until the liability is settled.
16. Revenue
  Revenue from contracts with customers is recognized by applying the following five steps: Step 1: Identify the contract with a customer
  Step 2: Identify the performance obligations in the contract Step 3: Determine the transaction price
  Step 4: Allocate the transaction price to the performance obligations in the contract Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation
  1. Sales of finished goods and merchandise
    Revenue from sale of finished goods and merchandise is recognized when the performance obligation is satisfied, considering the following indicators:
    - the Group has a present right to payment for the asset;
    - the customer has legal title to the asset;
    - the Group has transferred physical possession of the asset; and
    - the customer has accepted the asset.
      Revenue is measured at the amount after deducting the impact of trade discounts, cash discounts, rebates and returns from the consideration promised in the contract.
  2. License fee revenue
  Revenue arising from license agreements is recognized at a point in time or over time depending on the content of performance obligation(s).
  Variable consideration from contracts with customers are included in the transaction price only to the extent that is highly probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved.
17. Government Grants
  Government grants are recognized at fair value when there is reasonable assurance that the Group complies with the conditions attached to them and that the grants will be received.
  Government grants which are intended to compensate specific costs are recognized in profit or loss on a systematic basis over the period in which the Group recognizes the corresponding expenses.
  Government grants related to assets are recognized as deferred revenue and recognized in profit or loss on a systematic basis over the estimated useful lives of the relevant assets.
18. Income Taxes
  Income taxes comprise current and deferred income taxes.
  Current income taxes are measured at the amount expected to be paid to or recovered from the taxation authorities, using the tax rates that have been enacted or substantively enacted by the end of the reporting period. They are recognized in profit or loss, except to the extent that the taxes arise from transactions or events which are recognized either in other comprehensive income or directly in equity, or the taxes arise from business combinations.
  Deferred tax assets and liabilities are measured at the tax rates that are expected to apply to the period when the asset is realized or the liability is settled, based on tax rates that have been enacted or substantively enacted by the end of the reporting period. Deferred tax assets and liabilities are recognized for temporary differences between the carrying amount of assets or liabilities for accounting purpose and the tax basis, and unused tax losses and tax credits.
  Deferred tax assets are recognized to the extent that it is probable that future taxable profit will be available against which they can be utilized.
  When uncertainties exist if the taxing authorities will accept a particular tax treatment, the said uncertainties are reflected when determining the taxable profit, the carrying amount for the tax basis, unused tax losses and tax credits, and the tax rate.
  Deferred tax assets and liabilities are not recognized for temporary differences that arise from the initial recognition of goodwill or that arise from the initial recognition of assets or liabilities in transactions which are not business combinations and which do not give rise to equal taxable and deductible temporary differences at the time of the transaction and affect neither accounting profit nor taxable profit or tax loss.
  Deferred tax liabilities for taxable temporary differences associated with investments in subsidiaries and associates are recognized, except to the extent that the Group is able to control the timing of the reversal of the temporary differences and that it is probable that the temporary differences will not reverse in the foreseeable future. Deferred tax assets for deductible temporary differences arising from investments in subsidiaries and associates are recognized only to the extent that it is probable that the temporary differences will reverse in the foreseeable future and taxable profit will be available against which the temporary differences can be utilized.
  Deferred tax assets and deferred tax liabilities are offset if there is a legally enforceable right to offset current tax assets against current tax liabilities and the deferred tax assets and the deferred tax liabilities relate to income taxes levied by the same taxation authority on the same taxable entity.
Significant Accounting Judgments, Estimates and Assumptions
The preparation of these consolidated financial statements requires management of the Group to make judgments, estimates and assumptions that affect the amount of reported income, expenses, assets and liabilities as well as disclosure of contingent liabilities. However, due to uncertainty in the estimates and assumptions, it is possible that significant adjustments to carrying amounts of assets and liabilities may be required in future periods.
Significant items that required management to make estimates and judgments are as follows:
- Impairment of non-financial assets (Note 13. Property, Plant and Equipment, Note 14. Goodwill and Intangible Assets)
- Provisions (Note 19. Provisions)
- Measurement of defined benefit obligations (Note 20. Employee Benefits)
- Revenue recognition (Note 24. Revenue)

Standards and Interpretations Issued but Not Yet Adopted

The new and revised accounting standards and interpretations that have not been early adopted by the group are mainly as follows.

The Group is still in the progress of assessing the impact of adopting IFRS 18 on its consolidated financial statements.

IFRS		Date of Mandatory Application	Adoption by the Group	Overview
IFRS	Presentation and	Annual reporting	Year ending	Replacement of IAS 1
18	Disclosure	periods beginning	March 31, 2028	Presentation of
	in Financial	on or after January		Financial Statements
	Statements	1, 2027

Operating Segment Information

Reportable Segments
Disclosure is omitted as the Group has a single segment, "Pharmaceutical Operation".

Information about products and services Sales by products and services are as follows:

(Millions of JPY)

	Year ended March 31, 2025		Year ended March 31, 2026		Increase / (decrease)
	Amount	Ratio (%)	Amount	Ratio (%)	Amount	Ratio (%)
Prescription drugs	1,796,974	95.3	2,029,538	95.6	232,564	12.9
Healthcare (OTC) products	86,587	4.6	90,784	4.3	4,196	4.8
Others	2,693	0.1	2,722	0.1	28	1.0
Total	1,886,256	100.0	2,123,045	100.0	236,789	12.6

Information by geographical area

Revenue and non-current assets by geographical area are as follows:

Revenue

(Millions of JPY)

	Japan	United States	Europe	Other regions	Consolidated
Year ended March 31, 2025	583,802	642,215	418,211	242,026	1,886,256
Year ended March 31, 2026	580,112	749,401	497,375	296,155	2,123,045

Notes:

Revenue is classified according to the geographical location of customers.

Non-current assets

(Millions of JPY)

	Japan	United States	Europe	Other regions	Consolidated
As of March 31, 2025	385,120	291,395	152,481	13,787	842,785
As of March 31, 2026	389,929	330,282	194,563	20,206	934,982

Note:

Non-current assets are primarily presented based on the geographical location of assets, and are comprised of property, plant and equipment, goodwill and intangible assets.

Information on major customers

Customers for which sales were over 10% of total revenue in the Consolidated Statement of Profit or Loss are as follows:

(Millions of JPY)

Name of customer	Year ended March 31, 2025	Year ended March 31, 2026
McKesson Corp.	203,461	269,418
Cencora Inc.	207,389	251,034
Alfresa Holdings Corporation and its group companies	221,814	232,433

Business Combination

Significant business combination
Year ended March 31, 2025
There were no significant business combinations for the fiscal year ended March 31, 2025.
Year ended March 31, 2026
There were no significant business combinations for the fiscal year ended March 31, 2026.

Contingent consideration

The "contingent consideration" arises from the business combinations of HBT Labs, Inc.

The contingent consideration for the business combination with HBT Labs, Inc. is the estimated amount of future milestone payments and royalty payments over a certain period based on sales of the development pipeline, taking into account the time value of money.

The total amount of future payments that the Company may be required to make for all future milestones under the contingent consideration agreement is JPY3,198 million (before discount). There is no upper limit on the royalty payments to be made based on future sales of the development pipeline, and the estimated payment amounts are calculated based on future forecast sales. The exposure to foreign currency exchange risks at the reporting date is 9,667 thousand U.S. dollars. The impact of a 1% appreciation in the Yen against the U.S. dollar on profit before tax is JPY15 million at the reporting date.

The fair value hierarchy level for this contingent consideration is Level 3. The fair value change of contingent consideration is recognized in "Financial income" or "Financial expenses." The fair value hierarchy is summarized in Note 30 "Financial Instruments."

Reconciliation of the movement in the contingent consideration which is classified as Level 3 from the opening balances to the ending balances is as follows:

(Millions of JPY)

	Year ended March 31, 2025	Year ended March 31, 2026
Balance at the beginning of the year	2,402	1,445
Increase arising from business combination	-	-
Changes in fair value during the period	(927)	-
Settlement during the period	-	-
Exchange differences	(29)	100
Balance at the end of the year	1,445	1,546

Cash and Cash Equivalents

Details of "Cash and cash equivalents" are as follows:

(Millions of JPY)

	As of March 31, 2025	As of March 31, 2026
Cash and bank deposits	367,456	265,703
Short-term investments	272,382	184,103
Total	639,838	449,807

Note:

"Cash and cash equivalents" are classified as financial assets measured at amortized cost.

Trade and Other Receivables

Details of "Trade and other receivables" in the consolidated statement of financial position are as follows:

(Millions of JPY)

	As of March 31, 2025	As of March 31, 2026
Notes and accounts receivable - trade	436,177	522,678
Accounts receivable - other	37,116	85,600
Advance payments	129,022	109,683
Other receivables	17,452	24,884
Allowance for doubtful accounts	(666)	(1,700)
Total	619,101	741,145

Note:

"Notes and accounts receivable - trade" and "Accounts receivable - other" are classified as financial assets measured at amortized cost.

Other Financial Assets

Breakdown of Other Financial Assets

Breakdown of "Other financial assets" in the consolidated statement of financial position is as follows:

Current Assets

(Millions of JPY)

	As of March 31, 2025	As of March 31, 2026
Financial assets measured at amortized cost:
Bank deposits	6,472	41,010
Loans receivable	0	1
Bonds	74,127	61,654
Others	290	2,069
Total	80,890	104,736

Non-current Assets

(Millions of JPY)

	As of March 31, 2025	As of March 31, 2026
Financial assets measured at amortized cost:
Others	33,166	99,867
Financial assets measured at fair value through profit or loss:
Derivative assets	8	1
Bonds	751	804
Others	32,816	41,465
Financial assets measured at fair value through other comprehensive income:
Equity securities	70,655	50,291
Others	1,775	2,005
Total	139,175	194,435

Financial assets measured at fair value through other comprehensive income

Details of financial assets measured at fair value through other comprehensive income are as follows:

(Millions of JPY)

Equity Securities	Fair Value
Equity Securities	As of March 31, 2025	As of March 31, 2026
Listed
Shizuoka Financial Group, Inc.	9,947	13,963
Cuorips Inc.	8,310	7,010
Ultragenyx Pharmaceutical Inc.	6,735	4,167
MS&AD Insurance Group Holdings, Inc.	4,175	2,657
Qol Holdings Co., Ltd.	2,358	2,430
Tokio Marine Holdings, Inc.	1,977	1,679
Kissei Pharmaceutical Co., Ltd.	2,356	1,455
Iyogin Holdings, Inc.	826	1,330
AIN HOLDINGS INC.	574	641
HOKUYAKU TAKEYAMA Holdings, Inc.	388	403
Others	18,773	232
Unlisted	16,007	16,324

Note:

Equity securities are held to reinforce transactions and business relationships. These securities are designated as financial assets measured at fair value through other comprehensive income.

Derecognition of Financial Assets Measured at Fair value through Other Comprehensive Income

In the fiscal years ended March 31, 2025 and 2026, the Group disposed and derecognized some financial assets measured at fair value through other comprehensive income to improve the efficiency of assets by reassessing the business relationships.

Their fair value and accumulated gains and losses at the time of disposal are as follows:

(Millions of JPY)

	Year ended March 31, 2025		Year ended March 31, 2026
	Fair value	Accumulated gains (losses)	Fair value	Accumulated gains (losses)
Equity securities	19,241	14,848	16,402	13,648
Others	3	(8)	-	-

Note:

When financial assets measured at fair value through other comprehensive income are derecognized, gains and losses accumulated in other comprehensive income are reclassified to retained earnings.

Inventories

Details of "Inventories" in the consolidated statement of financial position are as follows:

(Millions of JPY)

	As of March 31, 2025	As of March 31, 2026
Merchandise and finished goods	229,010	207,482
Work in process	32,951	36,693
Raw materials	252,947	448,202
Total	514,910	692,378

Notes:

Inventories recognized as expenses and included in "Cost of sales" in the consolidated statement of profit or loss for the fiscal years ended March 31, 2025 and 2026 were JPY360,150 million and JPY403,472 million, respectively.
Write-down of inventories recognized during the period and included in "Cost of sales" in the consolidated statement of profit or loss for the fiscal years ended March 31, 2025 and 2026 were JPY17,253 million and JPY37,735 million, respectively.

Assets Held for Sale and Liabilities Directly Associated with Assets Held for Sale

Details of "Assets held for sale" and "Liabilities directly associated with assets held for sale" in the consolidated statement of financial position are as follows:

(Millions of JPY)

	As of March 31, 2025	As of March 31, 2026
Assets held for sale
Cash and cash equivalents	-	39,176
Trade and other receivables	-	25,779
Inventories	-	19,563
Goodwill	-	16,996
Investment in an associate	7,250	-
Others	-	20,647
Total	7,250	122,162
Liabilities directly associated with assets held for sale
Trade and other payables	-	25,171
Others	-	6,380
Total	-	31,552

Notes:

In the consolidated statement of financial position as of March 31, 2025, "Assets held for sale" included the remaining interest in Daiichi Sankyo Espha Co., Ltd. (29% of the total issued shares), and the transfer of the remaining interest was completed on April 1, 2025.
At the Board of Directors held on March 31, 2026, the Company resolved to transfer all of its shares in Daiichi Sankyo Healthcare Co., Ltd., a subsidiary of the Company, to Suntory Holdings Limited and entered into a stock transfer agreement with Suntory Holdings Limited on April 15, 2026. As a result, as it became certain that the Company would lose control over Daiichi Sankyo Healthcare Co., Ltd., the assets and liabilities of Daiichi Sankyo Healthcare Co., Ltd. and its subsidiaries have been classified as "Assets held for sale" and "Liabilities directly associated with assets held for sale," respectively, as of March 31, 2026. The cumulative amount of other comprehensive income related to "Assets held for sale" is JPY5,853 million (credit), which is included in "Other components of equity" in the consolidated statement of financial position as of March 31, 2026.

Property, Plant and Equipment

Reconciliation of carrying amount

Reconciliation of the carrying amount and details of acquisition cost, accumulated depreciation and accumulated impairment loss of "Property, plant and equipment" in the consolidated statement of financial position are as follows:

Acquisition cost

(Millions of JPY)

	Land, buildings and structures	Machinery and vehicles	Tools, furniture and fixtures	Construction in progress	Total
Balance as of April 1, 2024	488,246	219,328	122,734	112,563	942,872
Individual acquisitions	48,376	37,976	14,907	107,297	208,557
Sales or disposals	(3,341)	(6,230)	(15,568)	(0)	(25,140)
Exchange differences	(2,147)	(1,212)	(405)	(1,117)	(4,882)
Other increases and decreases (Note)	673	(31)	(540)	(81,738)	(81,636)
Balance as of March 31, 2025	531,808	249,830	121,127	137,004	1,039,770
Individual acquisitions	30,738	38,232	18,410	128,242	215,623
Sales or disposals	(3,306)	(14,091)	(4,473)	(4,840)	(26,712)
Reclassification to assets held for sale	(8,228)	(303)	(1,134)	-	(9,667)
Exchange differences	15,223	8,482	3,525	10,301	37,532
Other increases and decreases (Note)	(97)	18,111	(18,623)	(81,857)	(82,467)
Balance as of March 31, 2026	566,136	300,260	118,832	188,850	1,174,080

Note:

This was mainly due to the reclassification of accounts.

Accumulated depreciation and accumulated impairment loss

(Millions of JPY)

	Land, buildings and structures	Machinery and vehicles	Tools, furniture and fixtures	Construction in progress	Total
Balance as of April 1, 2024	262,680	163,255	95,244	-	521,180
Depreciation	22,031	14,230	10,252	-	46,513
Impairment loss	16	97	10	-	124
Sales or disposals	(3,169)	(5,779)	(15,478)	-	(24,427)
Exchange differences	(700)	(722)	(270)	-	(1,693)
Other increases and decreases	(14)	(20)	(409)	-	(444)
Balance as of March 31, 2025	280,843	171,060	89,349	-	541,253
Depreciation	24,767	17,970	11,278	-	54,016
Impairment loss	-	-	-	4,840	4,840
Sales or disposals	(3,069)	(12,489)	(4,449)	(4,840)	(24,848)
Reclassification to assets held for sale	(6,999)	(270)	(896)	-	(8,166)
Exchange differences	4,694	4,732	2,296	-	11,723
Other increases and decreases	(127)	5,229	(6,404)	-	(1,302)
Balance as of March 31, 2026	300,109	186,232	91,174	-	577,516

Carrying amounts

(Millions of JPY)

	Land, buildings and structures	Machinery and vehicles	Tools, furniture and fixtures	Construction in progress	Total
Balance as of April 1, 2024	225,566	56,072	27,489	112,563	421,692
Balance as of March 31, 2025	250,964	78,769	31,778	137,004	498,517
Balance as of March 31, 2026	266,027	114,028	27,658	188,850	596,563

Note:

Depreciation of property, plant and equipment is included in "Cost of sales," "Selling, general and administrative expenses," and "Research and development expenses" in the consolidated statement of profit or loss.

Impairment of Property, Plant and Equipment
The Group performed impairment testing for certain property, plant and equipment for which indicators of impairment were identified.
As a result of the impairment testing, impairment loss of JPY124 million and JPY4,840 million were recognized for the fiscal year ended March 31, 2025 and 2026, respectively, and recorded in "Cost of sales," "Selling, general and administrative expenses" in the consolidated statement of profit or loss.

Goodwill and Intangible Assets

Reconciliation of Carrying Amount

Reconciliation of the carrying amount and details of acquisition cost, accumulated amortization and accumulated impairment loss of "Goodwill" and "Intangible assets" in the consolidated statement of financial position are as follows:

Acquisition cost

(Millions of JPY)

	Goodwill	Intangible Assets
	Goodwill	In-process research and development	Commercial rights and trademarks	Software	Total
Balance as of April 1, 2024	108,498	14,041	372,430	25,231	411,702
Individual acquisitions	-	74,297	5,293	18,241	97,832
Sales or disposals	-	(2,970)	(7,774)	(2,929)	(13,673)
Exchange differences	(1,064)	(978)	(3,278)	(306)	(4,562)
Other increases and decreases	995	(1,912)	1,772	(3,150)	(3,291)
Balance as of March 31, 2025	108,429	82,477	368,442	37,087	488,006
Individual acquisitions	-	5	553	22,757	23,315
Sales or disposals	-	(851)	(1,599)	(1,561)	(4,012)
Reclassification to assets held for sale	(16,996)	-	(2,561)	(1,673)	(4,235)
Exchange differences	5,920	3,533	24,582	1,608	29,724
Other increases and decreases	-	-	(51)	(1,550)	(1,601)
Balance as of March 31, 2026	97,353	85,163	389,366	56,668	531,197

Accumulated amortization and accumulated impairment loss

(Millions of JPY)

	Goodwill	Intangible Assets
	Goodwill	In-process research and development	Commercial rights and trademarks	Software	Total
Balance as of April 1, 2024	-	307	225,959	17,134	243,401
Amortization	-	-	20,411	1,517	21,928
Impairment loss	-	2,970	-	-	2,970
Sales or disposals	-	(2,970)	(7,682)	(2,927)	(13,580)
Exchange differences	-	-	(2,325)	(225)	(2,551)
Other increases and decreases	-	-	(3)	2	(0)
Balance as of March 31, 2025	-	307	236,358	15,501	252,167
Amortization	-	-	20,364	3,032	23,397
Impairment loss	-	851	275	-	1,127
Sales or disposals	-	(851)	(1,241)	(907)	(3,000)
Reclassification to assets held for sale	-	-	(80)	(531)	(611)
Exchange differences	-	-	15,819	1,238	17,057
Other increases and decreases	-	-	(3)	(1)	(5)
Balance as of March 31, 2026	-	307	271,493	18,332	290,133

Carrying amounts

(Millions of JPY)

	Goodwill	Intangible Assets
	Goodwill	In-process research and development	Commercial rights and trademarks	Software	Total
Balance as of April 1, 2024	108,498	13,733	146,471	8,096	168,300
Balance as of March 31, 2025	108,429	82,169	132,083	21,585	235,839
Balance as of March 31, 2026	97,353	84,855	117,872	38,335	241,064

Note:

Amortization of intangible assets is included in "Cost of sales," "Selling, general and administrative expenses" and "Research and development expenses" in the consolidated statement of profit or loss.

Significant Goodwill and Intangible Assets
The Group allocated major goodwill to the cash-generating unit of the prescription drug business, and the carrying amount of goodwill allocated as of March 31, 2025 and 2026 was JPY75,828 million and JPY80,663 million, respectively.
The carrying amount of intangible assets mainly consists of:
- Commercial rights of Bempedoic Acid owned by Daiichi Sankyo Europe GmbH of JPY42,662 million and JPY41,787 million as of March 31, 2025 and 2026, respectively, which are amortized based on the straight-line method and the remaining amortization period as of March 31, 2026 was 6 years.
- Commercial rights related to Quizartinib owned by Ambit Biosciences Corporation of JPY27,625 million and JPY25,905 million as of March 31, 2025 and 2026, respectively, which are amortized based on the straight-line method and the remaining amortization period as of March 31, 2026 was 7 years.
- Commercial rights related to Paclitaxel owned by American Regent, Inc. of JPY18,257 million and JPY17,949 million as of March 31, 2025 and 2026, respectively, which are amortized based on the straight-line method and the remaining amortization period as of March 31, 2026 was 11 years.
- In-process research and development for MK-6070 of JPY47,754 million and JPY50,842 million as of March 31, 2025 and 2026 , respectively, in connection with the expansion of the joint development and commercialization agreement with Merck & Co., Inc., Rahway, N.J., USA.
- In-process research and development for DS-3939 of JPY22,691 million and JPY22,691 million as of March 31, 2025 and 2026, respectively.
Research and Development Expenditure
Research expenditure and development expenditure which do not meet the criteria for capitalization are expensed when incurred. The amount of expensed research and development expenditure were JPY435,965 million and JPY466,005 million for the fiscal years ended March 31, 2025 and 2026, respectively.
Impairment of Goodwill
The Group performs impairment testing for goodwill annually and at any time there is an indication that goodwill may be impaired. Impairment tests for goodwill for the cash-generating unit of the prescription drug business were performed as follows:
The recoverable amount was estimated based on value in use using the mid-term plan through fiscal 2030, which was approved by management, and the valuation included a terminal value assuming a growth rate of 0% after fiscal 2031.
The value in use was calculated using a pre-tax discount rate and exceeded the carrying amount, therefore no impairment loss was recognized for the fiscal year ended March 31, 2026. The pre-tax discount rates for the fiscal year ended March 31, 2025 and 2026 were 8.2% and 7.7%, respectively. The value in use exceeded the carrying amount, and the Group determined that the possibility of the value in use becoming lower than the carrying amount was remote, even if the discount rate were to increase within a reasonable range.
Impairment of Intangible Assets
The Group performs impairment testing for intangible assets which indicate impairment at all such times and for intangible assets not yet available for use annually and at any time there is an indication that an asset may be impaired.
The recoverable amount of an intangible asset is the higher of its fair value less costs of disposal and its value in use, which is calculated based on risk-adjusted future cash flows discounted by an appropriate discount rate. If the carrying amount of an intangible asset exceeds the recoverable amount, an impairment loss is recognized in profit or loss and the carrying amount is reduced to the recoverable amount.
For measurement of the value in use, the Group considers the possibility that the manufacturing and marketing of new products are approved, sales forecasts of products and other factors. Due to uncertainty in the underlying assumptions, it is possible that actual results may differ and, as a result, significant adjustments in the amount of intangible assets may be required in the consolidated financial statements for the year ending March 31, 2027.
As a result of the impairment testing, impairment losses of JPY2,970 million and JPY1,127 million were recognized for the fiscal years ended March 31, 2025 and 2026, respectively, and recorded in "Selling, general and administrative expenses" and "Research and development expenses" in the consolidated statement of profit or loss.

Investments Accounted for Using the Equity Method

Carrying amounts of investments in associates accounted for using the equity method are as follows:

(Millions of JPY)

	As of March 31, 2025	As of March 31, 2026
Carrying amounts of investments in associates	5,600	4,918

Financial information of associates accounted for using the equity method is as follows. These amounts are after adjustment for the Group's ownership ratio.

(Millions of JPY)

	Year ended March 31, 2025	Year ended March 31, 2026
Profit for the year	1,457	1,325
Other comprehensive income	-	-
Total comprehensive income for the year	1,457	1,325

Income Taxes

Deferred Tax Assets and Liabilities

Sources of "Deferred tax assets" and "Deferred tax liabilities" are as follows:

Year ended March 31, 2025

(Millions of JPY)

	Balance as of April 1, 2024	Recognized in profit or loss	Recognized in other comprehensive income	Others	Balance as of March 31, 2025
Deferred tax assets
Prepaid outsourced research expenses and co-development expenses	20,743	(1,309)	-	-	19,434
Depreciation and amortization	35,403	(2,727)	-	-	32,675
Unrealized gain and valuation loss of inventories	77,275	8,252	-	-	85,528
Unused tax losses	4,105	(1,530)	-	-	2,574
Accrued expenses	44,220	7,987	-	-	52,207
Valuation loss of securities	1,300	160	-	-	1,460
Impairment loss	4,180	(506)	-	-	3,673
Lease liabilities	13,639	347	-	-	13,987
Capitalized research expenses	72,247	30,255	-	-	102,502
Provisions	6,915	(2,424)	-	-	4,491
Others	50,327	7,446	(101)	-	57,671
Total	330,359	45,951	(101)	-	376,209
Deferred tax liabilities
Intangible assets	12,457	3,568	-	-	16,025
Financial assets measured at fair value through other comprehensive income	18,088	-	2,793	(4,334)	16,547
Post-employment benefit assets	11,854	(2,375)	2,023	-	11,502
Reserve for advanced depreciation of property, plant and equipment	4,235	(81)	-	-	4,153
Right-of-use assets	11,757	440	-	-	12,197
Others	35,471	(13,640)	287	(287)	21,830
Total	93,863	(12,088)	5,104	(4,622)	82,256
Net balance	236,496	58,040	(5,206)	4,622	293,952

Notes:

The difference between the total amounts recognized in profit or loss and other comprehensive income in the table above and the total deferred income taxes in profit or loss and total income taxes recognized through other comprehensive income, respectively, relates to income tax expenses associated with foreign currency translation differences.
Capitalized research expenses are the research expenses that have been made eligible for capitalization and amortization for tax purposes in the United States.
In the year ended March 31, 2025, "Provisions" that were included in "Others" under deferred tax assets have been separately presented starting from the year ended March 31, 2026, as their monetary materiality has increased. Accordingly, the comparative information has been reclassified.

Year ended March 31, 2026

(Millions of JPY)

	Balance as of April 1, 2025	Recognized in profit or loss	Recognized in other comprehensive income	Others	Balance as of March 31, 2026
Deferred tax assets
Prepaid outsourced research expenses and co-development expenses	19,434	(4,239)	-	-	15,194
Depreciation and amortization	32,675	(9,388)	-	-	23,287
Unrealized gain and valuation loss of inventories	85,528	67,931	-	-	153,459
Unused tax losses	2,574	434	-	-	3,009
Accrued expenses	52,207	17,018	-	-	69,225
Valuation loss of securities	1,460	(93)	-	-	1,367
Impairment loss	3,673	273	-	-	3,947
Lease liabilities	13,987	(1,347)	-	-	12,639
Capitalized research expenses	102,502	40,567	-	-	143,070
Provisions	4,491	61,768	-	-	66,259
Others	57,671	12,133	-	-	69,805
Total	376,209	185,058	-	-	561,268
Deferred tax liabilities
Intangible assets	16,025	(5,097)	-	-	10,927
Financial assets measured at fair value through other comprehensive income	16,547	-	2,339	(4,414)	14,472
Post-employment benefit assets	11,502	(2,230)	(1,969)	-	7,302
Reserve for advanced depreciation of property, plant and equipment	4,153	(154)	-	-	3,999
Right-of-use assets	12,197	(1,100)	-	-	11,097
Long-term accounts receivable	-	23,197	-	-	23,197
Others	21,830	6,371	34	(34)	28,202
Total	82,256	20,986	403	(4,448)	99,198
Net balance	293,952	164,072	(403)	4,448	462,069

Notes:

The difference between the total amounts recognized in profit or loss and other comprehensive income in the table above and the total deferred income taxes in profit or loss and total income taxes recognized through other comprehensive income, respectively, relates to income tax expenses associated with foreign currency translation differences.
Capitalized research expenses are the research expenses that have been made eligible for capitalization and amortization for tax purposes in the United States.
In the year ended March 31, 2025, "Provisions" that were included in "Others" under deferred tax assets have been separately presented starting from the year ended March 31, 2026, as their monetary materiality has increased. Accordingly, the comparative information has been reclassified.

Unrecognized Deferred Tax Assets

Deductible temporary differences, unused tax losses (detail by expiry) and unused tax credits (detail by expiry) for which deferred tax assets are not recognized in the consolidated statement of financial position are as follows:

(Millions of JPY)

	As of March 31, 2025	As of March 31, 2026
Deductible temporary differences	57,166	52,861
Unused tax losses
Within 1 year	1,488	-
Over 1 year within 5 years	7,166	2,071
Over 5 years	31,027	32,357
Total	39,681	34,428
Unused tax credits
Within 1 year	98	-
Over 1 year within 5 years	287	-
Over 5 years	1,802	-
Total	2,188	-

Unrecognized Deferred Tax Liabilities
The total temporary differences associated with equity investments in subsidiaries and associates for which deferred tax liabilities were not recognized were JPY181,544 million and JPY316,923 million as of March 31, 2025 and 2026, respectively. When the Group can control the timing of the reversal of the temporary differences and it is not probable that the temporary differences will be reversed in the foreseeable future, deferred tax liabilities are not recognized.

Income Taxes Recognized through Profit or Loss

Details of income taxes recognized through profit or loss are as follows:

(Millions of JPY)

	Year ended March 31, 2025	Year ended March 31, 2026
Current period income taxes	119,848	158,498
Deferred income taxes Origination and reversal of temporary differences Change in income tax rate or imposition of new taxation Adjustments and reversals of deferred tax assets	(57,810) (3,143) 980	(149,496) (382) (5,060)
Total	(59,973)	(154,939)
Total income tax expenses	59,874	3,558

Income Taxes Related to Items in Other Comprehensive Income

Details of income taxes recognized through other comprehensive income are as follows:

(Millions of JPY)

	Year ended March 31, 2025			Year ended March 31, 2026
	Before tax effect	Tax effect	After tax effect	Before tax effect	Tax effect	After tax effect
Financial assets measured at fair value through other comprehensive income	8,276	(3,023)	5,252	6,868	(2,114)	4,753
Remeasurements of defined benefit plans	5,744	(2,041)	3,702	(6,938)	1,956	(4,981)
Exchange differences on translation of foreign operations	(15,790)	-	(15,790)	50,185	-	50,185
Cash flow hedges	1,275	(389)	886	111	(34)	77
Total	(494)	(5,454)	(5,948)	50,226	(192)	50,034

Reconciliation of Effective Tax Rate

Major sources of differences between the statutory tax rate and effective tax rate are as follows:

	Year ended March 31, 2025	Year ended March 31, 2026
Statutory tax rate	30.5%	30.5%
Permanent non-deductible expenses such as entertainment expenses	2.7%	1.9%
Permanent non-taxable income such as dividends received	(0.2%)	(0.5%)
Changes in unrecognized deferred tax assets	0.0%	0.0%
Effect of different tax rates in foreign jurisdictions	(2.0%)	1.6%
Tax credit for research and development expenses	(11.6%)	(23.8%)
Other tax credits	(3.4%)	(6.5%)
Adjustment to period-end deferred tax assets due to change in tax rate	0.0%	(0.1%)
Foreign withholding tax on dividends from foreign subsidiaries	0.3%	0.5%
Impact of liquidation of consolidated subsidiaries	0.0%	(5.7%)
Others	0.5%	3.5%
Effective tax rate	16.8%	1.4%

Notes:

The Company is subject to corporate tax, inhabitant tax, and enterprise tax, which is tax deductible against taxable income for corporate tax purposes when paid. The applicable tax rate based on these taxes was 30.5% for the fiscal years ended March 31, 2025 and 2026. The statutory tax rate applied in the calculation of deferred tax assets and liabilities was 30.5% for amounts expected to be recovered or settled during the period from April 1, 2025 to March 31, 2026 in the year ended March 31, 2025, and 31.4% for those expected to be recovered or settled on or after April 1, 2026, in the year ended March 31, 2025, and 31.4% in the year ended March 31, 2026. Overseas operations are subject to income taxes of the jurisdictions in which they are located.
Tax credit for research and development expenses mainly arises in Japan and the United States.
In the year ended March 31, 2025, "Impact of liquidation of consolidated subsidiaries" that were included in "Others" have been separately presented starting from the year ended March 31, 2026, as their monetary materiality has increased. Accordingly, the comparative information has been reclassified.

Global Minimum Tax
In Japan, a corporate tax corresponding to the global minimum tax was established in the 2023 tax reform (hereinafter referred to as "Japan's Global Minimum Tax"), and the Tax Reform Act ("Act for Partial Revision of the Income Tax Act, etc." (Act No. 3 of 2023)) (hereinafter referred to as the "Revised Corporation Tax Act"), together
with provisions related to it, was enacted on March 28, 2023. The Revised Corporation Tax Act introduced the Income Inclusion Rule (IIR), which is one of the BEPS Global Minimum Tax rules (hereinafter referred to as "Pillar Two model rules"). Effective from the fiscal year ended March 31, 2025, an additional tax has been imposed on parent companies located in Japan until the tax burden of their subsidiaries and other affiliated entities reaches the minimum tax rate (15%).
The Group has applied the temporary exemption set forth in IAS 12 "Income Taxes" and has not recognized deferred tax assets and liabilities related to income taxes arising from tax law enacted or substantively enacted to implement the Pillar Two model rules (hereinafter referred to as "Pillar Two income taxes"), also has not included such amounts in the financial statement disclosures.
The impact of Pillar Two income taxes related to Japan's Global Minimum Tax on the Group's consolidated financial statements is not material.

Trade and Other Payables

Details of "Trade and other payables" in the consolidated statement of financial position are as follows:

(Millions of JPY)

	As of March 31, 2025	As of March 31, 2026
Notes and accounts payable - trade	92,757	84,882
Accounts payable - other	221,100	252,537
Others	266,099	259,436
Total	579,957	596,856

Note:

"Notes and accounts payable - trade" and "Accounts payable - other" are classified as financial liabilities measured at amortized cost.

Bonds and Borrowings, and Other Financial Liabilities

Breakdown of Bonds and Borrowings

Breakdown of "Bonds and borrowings" in the consolidated statement of financial position is as follows:

Current Liabilities

(Millions of JPY)

As of March 31, 2025

As of March 31, 2026

Financial liabilities measured at amortized cost:

Other borrowings

399

404

Total

399

404

Non-current Liabilities

(Millions of JPY)

As of March 31, 2025

As of March 31, 2026

Financial liabilities measured at amortized cost: Unsecured corporate bonds

Other borrowings

99,712

1,220

299,261

816

Total

100,933

300,077

Breakdown of Other Financial Liabilities

Breakdown of "Other financial liabilities" in the consolidated statement of financial position is as follows:

Current Liabilities

(Millions of JPY)

As of March 31, 2025

As of March 31, 2026

Financial liabilities measured at fair value through profit or loss:

Derivative liabilities

Lease liabilities

14,714

13,625

Total

14,720

13,630

Non-current Liabilities

(Millions of JPY)

As of March 31, 2025

As of March 31, 2026

Financial liabilities measured at amortized cost:

Lease liabilities

3,830

39,845

3,273

35,945

Total

43,675

39,219

Terms of Bonds

Terms of bonds are as follows:

(Millions of JPY)

Company name	Name of bond	Date of issuance	As of March 31, 2025	As of March 31, 2026	Interest rate	Maturity date
Daiichi Sankyo Company, Limited	5th Unsecured corporate bonds	July 25, 2016	75,000	75,000	0.81%	July 25, 2036
Daiichi Sankyo Company, Limited	6th Unsecured corporate bonds	July 25, 2016	25,000	25,000	1.20%	July 25, 2046
Daiichi Sankyo Company, Limited	7th Unsecured corporate bonds	Oct 10, 2025	-	20,000	1.26%	Oct 10, 2028
Daiichi Sankyo Company, Limited	8th Unsecured corporate bonds	Oct 10, 2025	-	70,000	1.60%	Oct 10, 2030
Daiichi Sankyo Company, Limited	9th Unsecured corporate bonds	Oct 10, 2025	-	70,000	1.88%	Oct 8, 2032
Daiichi Sankyo Company, Limited	10th Unsecured corporate bonds	Oct 10, 2025	-	40,000	2.15%	Oct 10, 2035
Total	-	-	100,000	300,000	-	-

Terms of Borrowings

Terms of borrowings are as follows:

(Millions of JPY)

	Provision for loss compensation	Environmental measures	Others	Total
Balance as of April 1, 2024	-	19,639	9,774	29,414
Increase during the period	-	-	4,232	4,232
Utilized	-	(6,510)	(7,669)	(14,179)
Reversed unused	-	(160)	(428)	(588)
Interest cost due to unwinding of discount	-	-	11	11
Exchange differences	-	-	(56)	(56)
Other increases and decreases	-	-	0	0
Balance as of March 31, 2025	-	12,969	5,865	18,835
Current liabilities	-	1,385	4,419	5,804
Non-current liabilities	-	11,583	1,446	13,030
Total	-	12,969	5,865	18,835

	Provision for loss compensation	Environmental measures	Others	Total
Balance as of April 1, 2025	-	12,969	5,865	18,835
Increase during the period	182,183	16,153	2,974	201,311
Utilized	-	(1,930)	(2,652)	(4,582)
Reversed unused	-	-	(207)	(207)
Interest cost due to unwinding of discount	-	-	12	12
Exchange differences	-	-	462	462
Other increases and decreases	-	-	(1,449)	(1,449)
Balance as of March 31, 2026	182,183	27,192	5,007	214,383
Current liabilities	36,075	10,460	3,274	49,811
Non-current liabilities	146,108	16,731	1,732	164,572
Total	182,183	27,192	5,007	214,383